INSMED Inc

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

INSM$119.49+2.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Comprehensive Loss (unaudited) for the and

Consolidated Statements of Comprehensive Loss (unaudited)

(in thousands, except per share data)

	Three Months Ended March 31,
	2025	2024
Product revenues, net	$92,823	$75,500
Operating expenses:
Cost of product revenues (excluding amortization of intangible assets)	21,278	17,457
Research and development	152,577	121,083
Selling, general and administrative	147,545	93,102
Amortization of intangible assets	1,263	1,263
Change in fair value of deferred and contingent consideration liabilities	18,300	(11,900)
Total operating expenses	340,963	221,005
Operating loss	(248,140)	(145,505)
Investment income	13,906	8,783
Interest expense	(21,569)	(21,042)
Change in fair value of interest rate swap	—	2,362
Other income (expense), net	132	(1,100)
Loss before income taxes	(255,671)	(156,502)
Provision for income taxes	912	589
Net loss	$(256,583)	$(157,091)
Basic and diluted net loss per share	$(1.42)	$(1.06)
Weighted average basic and diluted common shares outstanding	180,860	148,456
Net loss	$(256,583)	$(157,091)
Other comprehensive income (loss):
Foreign currency translation gains (losses)	1,828	(855)
Unrealized loss on marketable securities	(441)	(36)
Total comprehensive loss	$(255,196)	$(157,982)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.